beromuzumab

Beromuzumab is a monoclonal antibody investigated for the treatment of advanced malignancies, specifically hepatocellular carcinoma (HCC). According to clinical trial documentation (e.g., ChiCTR2600117101), it is evaluated in combination with the multi-kinase inhibitor anlotinib and stereotactic body radiation therapy (SBRT) for patients with oligometastatic HCC who have progressed on first-line targeted immunotherapy. The drug's name and clinical application suggest it functions as an angiogenesis inhibitor, likely targeting vascular endothelial growth factor (VEGF). However, "beromuzumab" does not appear in the World Health Organization's International Nonproprietary Names (INN) database and is widely considered a typographical error for **bevacizumab** in the source literature.

Other names

beromuzumab